Stabilis

Vecuronium bromide



Noms commerciaux

Blok-L	Turquie
Norcuron	Grèce, Pologne, Portugal, Turquie
Vecuronium	Grande Bretagne

Stabilité des solutions

		0,04 mg/ml	15-25°C		24			3630
PVC		0,04 mg/ml	15-25°C		24			3630
PP		1 mg/ml	23-25°C	?	21			2209
PP		1 mg/ml	3-5°C	?	21			2209

Stabilité en mélange

		0,52 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4	813
		0.5 mg/ml	25°C	?	Palonosetron hydrochloride : 25.6 µg/ml	4	2227
PP	Ø	0,127 mg/ml	22°C		Propofol : 0,0095 mg/ml Fentanyl citrate : 0,0024 µg/ml	1	1863

Compatibilités

		Vecuronium bromide : 1 mg/ml Alprostadil : 15 µg/ml		3201
		Vecuronium bromide : 0.1 mg/ml Aminophylline : 1 mg/ml		402
		Vecuronium bromide : 1 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Vecuronium bromide : 1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Vecuronium bromide : 1 mg/ml Caffeine : 10 mg/ml		4837
		Vecuronium bromide : 1 mg/ml Caffeine citrate : 20 mg/ml		4837
		Vecuronium bromide : 0.1 mg/ml Cefazolin sodium : 10 mg/ml		402
		Vecuronium bromide : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Vecuronium bromide : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Vecuronium bromide : 0.1 mg/ml Cefuroxime sodium : 7.5 mg/ml		402
		Vecuronium bromide : 0.1 mg/ml Cimetidine hydrochloride : 6 mg/ml		402
		Vecuronium bromide : 0.2 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Vecuronium bromide : 0.1 mg/ml Co-trimoxazole : 3.2/0.64 mg/ml		402
		Vecuronium bromide : 0.1 mg/ml Diazepam : 5 mg/ml		402
		Vecuronium bromide : 1 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Vecuronium bromide : 0.1 mg/ml Dobutamine hydrochloride : 1 mg/ml		402
		Vecuronium bromide : 1 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Vecuronium bromide : 0.1 mg/ml Dopamine hydrochloride : 1.6 mg/ml		402
		Vecuronium bromide : 1 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Vecuronium bromide : 0.1 mg/ml Epinephrine hydrochloride : 4 µg/ml		402
		Vecuronium bromide : 1 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Vecuronium bromide : 1 mg/ml Eravacycline : 0,6 mg/ml		4434
		Vecuronium bromide : 0.1 mg/ml Esmolol hydrochloride : 10 mg/ml		402
		Vecuronium bromide : 1 mg/ml Etomidate : 2 mg/ml	∅	319

		Vecuronium bromide : 0.2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Vecuronium bromide : 0.1 mg/ml Fentanyl citrate : 10 µg/ml		402
		Vecuronium bromide : 1 mg/ml Fentanyl citrate : 50 µg/ml		314
		Vecuronium bromide : 1 mg/ml Fluconazole : 2 mg/ml		255
		Vecuronium bromide : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Vecuronium bromide : 0.1 mg/ml Gentamicin sulfate : 2 mg/ml		402
		Vecuronium bromide : 1 mg/ml Heparin sodium : 100 UI/ml		314
		Vecuronium bromide : 0.1 mg/ml Heparin sodium : 40 UI/ml		402
		Vecuronium bromide : 2 mg/ml		939
		Vecuronium bromide : 1 mg/ml Furosemide : 10 mg/ml		314
		Vecuronium bromide : 0.2 mg/ml Hetastarch : 60 mg/ml		1721
		Vecuronium bromide : 0.1 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		402
		Vecuronium bromide : 1 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Vecuronium bromide : 2 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Vecuronium bromide : 1 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Vecuronium bromide : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Vecuronium bromide : 0.1 mg/ml Isoprenaline hydrochloride : 0.004 mg/ml		402
		Vecuronium bromide : 1 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Vecuronium bromide : 1 mg/ml Linezolid : 2 mg/ml	∅	1925
		Vecuronium bromide : 1 mg/ml Lorazepam : 0.5 mg/ml		314
		Vecuronium bromide : 4 mg/ml Lorazepam : 0.33 mg/ml		186
		Vecuronium bromide : 0.1 mg/ml Lorazepam : 0.5 mg/ml		402
		Vecuronium bromide : 1 mg/ml Micafungin : 1.5 mg/ml		2108
		Vecuronium bromide : 0.1 mg/ml Midazolam hydrochloride : 0.05 mg/ml		402
		Vecuronium bromide : 1 mg/ml Midazolam hydrochloride : 2 mg/ml		314
		Vecuronium bromide : 4 mg/ml Midazolam hydrochloride : 5 mg/ml	∅	186

		Vecuronium bromide : 1 mg/ml Milrinone lactate : 0.2 mg/ml		314
		Vecuronium bromide : 2 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Vecuronium bromide : 0.1 mg/ml Morphine sulfate : 1 mg/ml		402
		Vecuronium bromide : 1 mg/ml Morphine sulfate : 2 mg/ml		314
		Vecuronium bromide : 1 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Vecuronium bromide : 0.1 mg/ml Nitroglycerin : 0.4 mg/ml		402
		Vecuronium bromide : 1 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Vecuronium bromide : 0.1 mg/ml Nitroprusside sodium : 0.2 mg/ml		402
		Vecuronium bromide : 1 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Vecuronium bromide : 1 mg/ml Palonosetron hydrochloride : 50 µg/ml		2227
		Vecuronium bromide Pantoprazole sodium		2090
		Vecuronium bromide : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Vecuronium bromide : 1 mg/ml Propofol : 10 mg/ml		300
		Vecuronium bromide : 1 mg/ml Propofol		660
		Vecuronium bromide : 1 mg/ml Propofol : 2 mg/ml		319
		Vecuronium bromide : 0.1 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		402
		Vecuronium bromide : 1 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
		Vecuronium bromide : 1 mg/ml Remimazolam : 5 mg/ml		4723
		Vecuronium bromide : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Vecuronium bromide : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Vecuronium bromide Thiopental sodium		3373
		Vecuronium bromide Thiopental sodium		2073
		Vecuronium bromide Thiopental sodium		3630
		Vecuronium bromide : 1 mg/ml Thiopental sodium : 25 mg/ml		314
		Vecuronium bromide : 1 mg/ml Thiopental sodium : 25 mg/ml		319
		Vecuronium bromide : 0.1 mg/ml Vancomycin hydrochloride : 5 mg/ml		402

Voie d'administration



Bibliographie

	Type	Source
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
255	Revue	Ishisaka DY. Visual compatibility of fluconazole with drugs given by continuous infusion. Am J Hosp Pharm 1994 ; 51: 2290,2292.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
319	Revue	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.

1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1863	Revue	Isert PR, Lee D, Naidoo D, Carasso ML, Kennedy RA. Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport. Journal of clinical anesthesia 1996 ; 8: 329-336.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2073	Revue	Taniguchi T, Yamamoto K, Kobayashi T. Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. Can J Anesth 1998 ; 45: 347-351.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2209	Revue	Johnson CE, Petrea Cober M. Stability of vecuronium in sterile water for injection stored in polypropylene syringes for 21 days. Am J Health-Syst Pharm 2007 ; 64, 22: 2356-2358.
2227	Revue	Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160.
3201	Revue	Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3373	Revue	Khan S, Stannard N, Greijn J. Precipitation of thiopental with muscle relaxants: a potential hazard. J R Soc Med Sh Rep 2011 ; 2: 58.
3630	Laboratoire	Vecuronium (Norcuron®) - Summary of Product Characteristics Merck Sharp Dohme 2012
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44

4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4419	Revue	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4723	Revue	Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4837	Revue	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.

Dictionnaire

	Curarisant		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		Lumière
	Heure		Polyvinyl chlorure
	Seringue polypropylène		Eau pour préparation injectable
	Non précisée		Jour
	Stabilité en mélange		Solvant
	Molécule		Glucose 5%
	Aucun		A l'abri de la lumière
	Compatibilités		Compatible
	Précipitation immédiate		Incompatible
	Chlorure de sodium 0,9%		Turbidité immédiate
	Nutrition parentérale (mélange binaire)		Solvant spécifique
	Instabilité de l'émulsion à 4 heures		Turbidité en 4 heures
	Incompatibilité non précisée		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Bibliographie		Dictionnaire